<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL. High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV. Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O’Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1, <strong>Schwartz JM,</strong> Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H,Dieterich DT, Branch AD, Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther. 2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL. Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma. In Rose BD, editor. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr. Clinical features, diagnosis, and screening for primary hepatocellular carcinoma. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr. Nonsurgical therapies for localized hepatocellular carcinoma. Up to date, Inc. Wellesley, MA, Updated 2014.<strong> </strong></li>
<li><strong>Schwartz JM</strong>. Approach to the patient with a focal liver lesion. Up to date Inc Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM. </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF. Prevalence and Natural History of Alcoholic Liver Disease. Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p> </p>
![http://www.montefiore.org/images/btns/MontefioreLogo2010.gif"](http://www.montefiore.org/images/btns/MontefioreLogo2010.gif"){kind=link}
![https://www.montefiore.org/sitemaker/graphics/smsorticondown.gif"](https://www.montefiore.org/sitemaker/graphics/smsorticondown.gif"){kind=link}
![http://www.montefiore.org/images/logos/CCTDcolor-sm.jpg"](http://www.montefiore.org/images/logos/CCTDcolor-sm.jpg"){kind=link}